DDRGK1 inhibitors are a class of chemical compounds designed to specifically inhibit the DDRGK1 protein, which is part of the UFM1 conjugation system. DDRGK1 plays a crucial role in regulating protein stability and function through its involvement in protein modification by the ubiquitin-like protein UFM1 (ubiquitin-fold modifier 1). This modification system is vital for various cellular processes, particularly in endoplasmic reticulum (ER)-related protein quality control, stress response, and homeostasis. DDRGK1 is a critical component in this pathway, acting as an adaptor protein that facilitates the interaction between UFM1 and its target proteins. By inhibiting DDRGK1, these compounds can disrupt the UFM1 modification process, leading to alterations in protein processing and signaling within cells.
Structurally, DDRGK1 inhibitors are designed to bind to key regions of the DDRGK1 protein, typically the active site or regions involved in protein-protein interactions that are essential for its function. These inhibitors can act in different ways, such as through competitive inhibition, where the inhibitor directly competes with UFM1 or its substrates, or through allosteric inhibition, where binding occurs at a separate site, inducing conformational changes that reduce DDRGK1's activity. The development and study of DDRGK1 inhibitors are important for understanding the specific biochemical pathways regulated by the UFM1 conjugation system. Investigating how these inhibitors affect DDRGK1's role in protein modification sheds light on its broader functions within the cell, including its impact on protein folding, degradation, and stress response pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, may affect protein degradation pathways involving DDRGK1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor, potentially impacting protein homeostasis related to DDRGK1 functions. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation, affecting ER stress and possibly DDRGK1 activity. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
HSP90 inhibitor, can impact protein folding processes related to DDRGK1's function. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Another HSP90 inhibitor, potentially influencing DDRGK1 associated pathways. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Inhibits dephosphorylation of eIF2α, affecting ER stress response which may be linked to DDRGK1. | ||||||
ISRIB | 1597403-47-8 | sc-488404 | 10 mg | $300.00 | 1 | |
Reverses the effects of eIF2α phosphorylation, potentially affecting DDRGK1-related stress response. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor, affects autophagy and could indirectly influence DDRGK1 function. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
Autophagy inhibitor, potentially impacting cellular processes involving DDRGK1. | ||||||